EquitySector - HealthcareVery High Risk
Regular
NAV (30-Jun-25)
Returns (Since Inception)
Fund Size
₹321 Cr
Expense Ratio
2.37%
ISIN
INF0QA701987
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
27 Dec 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-3.07%
— (Cat Avg.)
Equity | ₹306.52 Cr | 95.48% |
Others | ₹14.5 Cr | 4.52% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Divi's Laboratories Ltd | Equity | ₹27.97 Cr | 8.71% |
Sun Pharmaceuticals Industries Ltd | Equity | ₹25.1 Cr | 7.82% |
Cipla Ltd | Equity | ₹21.21 Cr | 6.61% |
Apollo Hospitals Enterprise Ltd | Equity | ₹18.82 Cr | 5.86% |
Net Receivables / (Payables) | Cash | ₹14.5 Cr | 4.52% |
Dr Reddy's Laboratories Ltd | Equity | ₹11.32 Cr | 3.52% |
Piramal Pharma Ltd | Equity | ₹11.25 Cr | 3.50% |
Biocon Ltd | Equity | ₹11 Cr | 3.43% |
Emcure Pharmaceuticals Ltd | Equity | ₹10.91 Cr | 3.40% |
Glenmark Pharmaceuticals Ltd | Equity | ₹9.03 Cr | 2.81% |
Neuland Laboratories Ltd | Equity | ₹8.87 Cr | 2.76% |
Syngene International Ltd | Equity | ₹8.5 Cr | 2.65% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹8.43 Cr | 2.63% |
Torrent Pharmaceuticals Ltd | Equity | ₹7.77 Cr | 2.42% |
Abbott India Ltd | Equity | ₹7.47 Cr | 2.33% |
Pfizer Ltd | Equity | ₹7.21 Cr | 2.24% |
Ipca Laboratories Ltd | Equity | ₹7.19 Cr | 2.24% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹6.67 Cr | 2.08% |
Rainbow Childrens Medicare Ltd | Equity | ₹6.44 Cr | 2.01% |
Zydus Wellness Ltd | Equity | ₹6.22 Cr | 1.94% |
Dr. Lal PathLabs Ltd | Equity | ₹6.1 Cr | 1.90% |
Vijaya Diagnostic Centre Ltd | Equity | ₹5.9 Cr | 1.84% |
Fortis Healthcare Ltd | Equity | ₹5.51 Cr | 1.72% |
Hindustan Unilever Ltd | Equity | ₹5.09 Cr | 1.58% |
Shaily Engineering Plastics Ltd | Equity | ₹5 Cr | 1.56% |
Alkem Laboratories Ltd | Equity | ₹4.87 Cr | 1.52% |
Orchid Pharma Ltd | Equity | ₹4.44 Cr | 1.38% |
Emami Ltd | Equity | ₹4.4 Cr | 1.37% |
Medi Assist Healthcare Services Ltd | Equity | ₹4.32 Cr | 1.35% |
Medplus Health Services Ltd | Equity | ₹4.29 Cr | 1.34% |
Jubilant Pharmova Ltd | Equity | ₹4.11 Cr | 1.28% |
Alembic Pharmaceuticals Ltd | Equity | ₹4.07 Cr | 1.27% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹3.94 Cr | 1.23% |
Lupin Ltd | Equity | ₹3.84 Cr | 1.20% |
Marico Ltd | Equity | ₹3.8 Cr | 1.18% |
AstraZeneca Pharma India Ltd | Equity | ₹3.62 Cr | 1.13% |
Mankind Pharma Ltd | Equity | ₹3.58 Cr | 1.12% |
Aurobindo Pharma Ltd | Equity | ₹2.87 Cr | 0.89% |
Nestle India Ltd | Equity | ₹2.4 Cr | 0.75% |
Neogen Chemicals Ltd | Equity | ₹1.58 Cr | 0.49% |
PB Fintech Ltd | Equity | ₹1.41 Cr | 0.44% |
Large Cap Stocks
31.41%
Mid Cap Stocks
31.23%
Small Cap Stocks
32.84%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹276.63 Cr | 86.17% |
Consumer Defensive | ₹21.9 Cr | 6.82% |
Basic Materials | ₹6.59 Cr | 2.05% |
Financial Services | ₹1.41 Cr | 0.44% |
Standard Deviation
This fund
--
Cat. avg.
16.03%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Since December 2024
Since December 2024
Since December 2024
ISIN INF0QA701987 | Expense Ratio 2.37% | Exit Load 1.00% | Fund Size ₹321 Cr | Age 6 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (30-Jun-25)
Returns (Since Inception)
Fund Size
₹321 Cr
Expense Ratio
2.37%
ISIN
INF0QA701987
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
27 Dec 2024
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-3.07%
— (Cat Avg.)
Equity | ₹306.52 Cr | 95.48% |
Others | ₹14.5 Cr | 4.52% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Divi's Laboratories Ltd | Equity | ₹27.97 Cr | 8.71% |
Sun Pharmaceuticals Industries Ltd | Equity | ₹25.1 Cr | 7.82% |
Cipla Ltd | Equity | ₹21.21 Cr | 6.61% |
Apollo Hospitals Enterprise Ltd | Equity | ₹18.82 Cr | 5.86% |
Net Receivables / (Payables) | Cash | ₹14.5 Cr | 4.52% |
Dr Reddy's Laboratories Ltd | Equity | ₹11.32 Cr | 3.52% |
Piramal Pharma Ltd | Equity | ₹11.25 Cr | 3.50% |
Biocon Ltd | Equity | ₹11 Cr | 3.43% |
Emcure Pharmaceuticals Ltd | Equity | ₹10.91 Cr | 3.40% |
Glenmark Pharmaceuticals Ltd | Equity | ₹9.03 Cr | 2.81% |
Neuland Laboratories Ltd | Equity | ₹8.87 Cr | 2.76% |
Syngene International Ltd | Equity | ₹8.5 Cr | 2.65% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹8.43 Cr | 2.63% |
Torrent Pharmaceuticals Ltd | Equity | ₹7.77 Cr | 2.42% |
Abbott India Ltd | Equity | ₹7.47 Cr | 2.33% |
Pfizer Ltd | Equity | ₹7.21 Cr | 2.24% |
Ipca Laboratories Ltd | Equity | ₹7.19 Cr | 2.24% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹6.67 Cr | 2.08% |
Rainbow Childrens Medicare Ltd | Equity | ₹6.44 Cr | 2.01% |
Zydus Wellness Ltd | Equity | ₹6.22 Cr | 1.94% |
Dr. Lal PathLabs Ltd | Equity | ₹6.1 Cr | 1.90% |
Vijaya Diagnostic Centre Ltd | Equity | ₹5.9 Cr | 1.84% |
Fortis Healthcare Ltd | Equity | ₹5.51 Cr | 1.72% |
Hindustan Unilever Ltd | Equity | ₹5.09 Cr | 1.58% |
Shaily Engineering Plastics Ltd | Equity | ₹5 Cr | 1.56% |
Alkem Laboratories Ltd | Equity | ₹4.87 Cr | 1.52% |
Orchid Pharma Ltd | Equity | ₹4.44 Cr | 1.38% |
Emami Ltd | Equity | ₹4.4 Cr | 1.37% |
Medi Assist Healthcare Services Ltd | Equity | ₹4.32 Cr | 1.35% |
Medplus Health Services Ltd | Equity | ₹4.29 Cr | 1.34% |
Jubilant Pharmova Ltd | Equity | ₹4.11 Cr | 1.28% |
Alembic Pharmaceuticals Ltd | Equity | ₹4.07 Cr | 1.27% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹3.94 Cr | 1.23% |
Lupin Ltd | Equity | ₹3.84 Cr | 1.20% |
Marico Ltd | Equity | ₹3.8 Cr | 1.18% |
AstraZeneca Pharma India Ltd | Equity | ₹3.62 Cr | 1.13% |
Mankind Pharma Ltd | Equity | ₹3.58 Cr | 1.12% |
Aurobindo Pharma Ltd | Equity | ₹2.87 Cr | 0.89% |
Nestle India Ltd | Equity | ₹2.4 Cr | 0.75% |
Neogen Chemicals Ltd | Equity | ₹1.58 Cr | 0.49% |
PB Fintech Ltd | Equity | ₹1.41 Cr | 0.44% |
Large Cap Stocks
31.41%
Mid Cap Stocks
31.23%
Small Cap Stocks
32.84%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹276.63 Cr | 86.17% |
Consumer Defensive | ₹21.9 Cr | 6.82% |
Basic Materials | ₹6.59 Cr | 2.05% |
Financial Services | ₹1.41 Cr | 0.44% |
Standard Deviation
This fund
--
Cat. avg.
16.03%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Since December 2024
Since December 2024
Since December 2024
ISIN INF0QA701987 | Expense Ratio 2.37% | Exit Load 1.00% | Fund Size ₹321 Cr | Age 6 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments